apoptosis. The long noncoding RNA (lncRNA) Saf was reported to participate in this process. LncRNAs are >200 nucleotide transcripts that form complexes with various RNA-binding proteins, including splicing factors, to regulate and diversify gene function. Last year, we reported that the 1.5-kb lncRNA Saf was regulated by GATA-1 and KLF1 and induced during maturation of human erythroid cells. As the precise mechanism of Saf function is unknown, we extend our fi ndings to include gene expression analysis, cellular localization, and identifi cation of Saf interacting proteins. For gene expression studies, two human cell lines, Jurkat T-cells and K562 erythroleukemia cells, were transduced with lentivirus particles encoding for Saf/ GFP or GFP alone. Total RNA was isolated from the resulting GFP+ cells and genome wide expression analyses performed on HG-U133_Plus2 cartridges. Saf over expression had no effect on global gene transcription, supporting a post-transcriptional role. To assess localization, total RNA was extracted from the nuclear and cytoplasmic fractions of MCF7 cells that endogenously express Saf. RT-PCR analysis revealed that Saf was localized in the nucleus and fraction purity verifi ed with the nuclear-retained 47S pre-rRNA. Saf associated proteins were isolated by RNA pulldown of in vitro transcribed Saf RNAs (-/+ Biotin-UTP) that were mixed with K562 nuclear lysates and recovered using anti-streptavidin beads. Mass spectrometry analysis identifi ed eight partners unique to biotinlabeled Saf. One protein with highest counts, human splicing factor (SPF45) also called RNA-binding motif protein 17 (RBM17), was confi rmed to interact with Saf by RNA co-immunoprecipation using SPF45-specifi c antibodies in nuclear lysates prepared from K562 cells with stable expression of Saf and RT-PCR. Specifi c interaction was demonstrated by the failure to detect Saf using either control IgG or GATA-1 antibodies. SPF45 regulates alternative splicing of FasR pre-mRNA by inducing exon 6 skipping to generate sFas proteins. To monitor this molecular event in maturing erythroid cells, we developed a qRT-PCR assay to indirectly measure this isoform (FasRExon6) as a ratio of total FasR mRNA levels and detected a 2.5-fold increase in these sFas-encoding transcripts in late stage adult BM-derived erythroblasts. Regulation of apoptosis is essential for erythropoiesis and many other developmental processes. Our fi nding that Saf participates in FasR alternative splicing through direct interaction with SPF45 reveals a novel layer of modulation of the cell death program that is required for the proper generation of mature red blood cells.
apoptosis. The long noncoding RNA (lncRNA) Saf was reported to participate in this process. LncRNAs are >200 nucleotide transcripts that form complexes with various RNA-binding proteins, including splicing factors, to regulate and diversify gene function. Last year, we reported that the 1.5-kb lncRNA Saf was regulated by GATA-1 and KLF1 and induced during maturation of human erythroid cells. As the precise mechanism of Saf function is unknown, we extend our fi ndings to include gene expression analysis, cellular localization, and identifi cation of Saf interacting proteins. For gene expression studies, two human cell lines, Jurkat T-cells and K562 erythroleukemia cells, were transduced with lentivirus particles encoding for Saf/ GFP or GFP alone. Total RNA was isolated from the resulting GFP+ cells and genome wide expression analyses performed on HG-U133_Plus2 cartridges. Saf over expression had no effect on global gene transcription, supporting a post-transcriptional role. To assess localization, total RNA was extracted from the nuclear and cytoplasmic fractions of MCF7 cells that endogenously express Saf. RT-PCR analysis revealed that Saf was localized in the nucleus and fraction purity verifi ed with the nuclear-retained 47S pre-rRNA. Saf associated proteins were isolated by RNA pulldown of in vitro transcribed Saf RNAs (-/+ Biotin-UTP) that were mixed with K562 nuclear lysates and recovered using anti-streptavidin beads. Mass spectrometry analysis identifi ed eight partners unique to biotinlabeled Saf. One protein with highest counts, human splicing factor (SPF45) also called RNA-binding motif protein 17 (RBM17), was confi rmed to interact with Saf by RNA co-immunoprecipation using SPF45-specifi c antibodies in nuclear lysates prepared from K562 cells with stable expression of Saf and RT-PCR. Specifi c interaction was demonstrated by the failure to detect Saf using either control IgG or GATA-1 antibodies. SPF45 regulates alternative splicing of FasR pre-mRNA by inducing exon 6 skipping to generate sFas proteins. To monitor this molecular event in maturing erythroid cells, we developed a qRT-PCR assay to indirectly measure this isoform (FasRExon6) as a ratio of total FasR mRNA levels and detected a 2.5-fold increase in these sFas-encoding transcripts in late stage adult BM-derived erythroblasts. Regulation of apoptosis is essential for erythropoiesis and many other developmental processes. Our fi nding that Saf participates in FasR alternative splicing through direct interaction with SPF45 reveals a novel layer of modulation of the cell death program that is required for the proper generation of mature red blood cells. Fetal gene transfer offers unique potential to achieve sustained transgene expression within rapidly cycling cell populations through transduction of tissue-specifi c stem cells. Due to its hormonally responsive nature, efforts at transduction of the mammary epithelium in non-transgenic animals have allowed only short-term expression. We have previously demonstrated the ability to selectively transduce a mammary epithelial stem cell population through early gestational intra-amniotic injection of targeted lentiviral vector. In addition to the obvious clinical applications of selective gene transfer, this technique offers intriguing potential as a novel method for the production of therapeutic proteins. Because our technique allows stable transgene expression in the mammary epithelium throughout the life of the animal, we hypothesized that engineered production of human therapeutic proteins could be achieved in breastmilk following early gestational intra-amniotic injection of lentiviral vector encoding for a secreted human protein under the control of the mammaryspecifi c Mouse Mammary Tumor Virus (MMTV) promoter. To test this hypothesis, we used the human factor IX protein to facilitate detection in protein-rich mouse breastmilk. A lentiviral vector was constructed using the entire MMTV LTR truncated by 25 bp at the 3' end[1] (courtesy Philip Leder) encoding for GFP and human factor IX. Vector was injected into the amniotic cavity (0.35 uL at 1.2 x 10^8 pfu/mL) of the E8-9 Balb/c fetus under ultrasound guidance. Surviving female pups were mated with Balb/c males and manually milked following intraperitoneal oxytocin injection (2 IU). Breastmilk was analyzed for the presence of human factor IX protein using ELISA with no mouse cross-reactivity. Based upon our vector screen results, our MMTV promoter shows strong GFP expression in both ducts and glands by fl uorescence stereomicroscopy, with very low level and sporadic expression in some cortical elements of the brain and no expression in any other tissue, including those of epithelial lineage. ELISA demonstrates signifi cant production of human factor IX protein in the breastmilk of injected animals, on the order of 250 ng/mL through 6 months of age. The sustained secretion of a human protein in the breastmilk of injected animals offers a novel method for the production of therapeutic proteins with important biotechnology implications. Among the challenges inherent in current methods are the complicated folding patterns necessary for the function of certain proteins. For such targets, in vitro methods may not be suffi cient to recapitulate the required structure, making in vivo methods far superior. Depending on the nature of the target, the development of transgenics may be fi nancially or biologically prohibitive. Our method offers a novel alternative to this costly and diffi cult process, allowing scaleable and sustained production of therapeutic proteins in breastmilk. 1. Muller, W.J., et al., Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 1988. 54 (1) Hemophilia B is an inherited bleeding disorder caused by the defi ciency of Factor IX (FIX), a functional clotting factor. Gene transduced cells are considered to be a useful tool in establishing cell-based gene therapies for diseases with monogenic plasma protein defi ciencies, while remaining need of improving survival of transplanted cells in vivo. Patient-derived adipose tissue-derived stem/stromal cells (ADSCs) is an attractive cell sources. This study explored the potential of ADSCs (mADSCs) for human FIX (hFIX) gene transduction with a self-inactivating lentivirus simian immunodefi ciency virus (SIV) vector in vitro and their ability to produce and secrete biologically active hFIX in vivo. The optimal SIV-vector dose for mADSCs transduction was determined by their transduction effi ciency and the production level of hFIX. Although the hFIX production levels into culture medium showed a slight decrease in the fi rst week, sustained production levels were observed for the duration of the study (up to 4 weeks). Clotting assay confi rmed that the hFIX produced by the ADSCs was biologically active clotting factor. For establishing a tissue engineering-based treatment modality with hFIX-transduced ADSCs, we created a contiguous cell sheet format of the hFIX-transduced ADSCs based on cell sheet engineering technology, and followed by their which was then transplanted into a subcutaneous space of mice. Transplantation of hFIX-transduced ADSC sheets (1 to 6 sheets) was found to be successfully engrafted in mice, and we observed a linear increase in plasma hFIX levels proportional to the number of transplanted sheets. The recipient mice that received 6 ADSC sheets demonstrated plasma hFIX level of 33.1 ± 6.5 ng/ml at day 1,. This plasma hFIX level of mice that received subcutaneous injection of ADSCs in suspension at the same cell number to the 6 ADSC sheets was 17.1±3.1 ng/ml, which was signifi cantly lower than the that of mice with ADSC sheets. The plasma hFIX levels were found to decrease as a function of time, which was correlated with histological fi ndings that the hFIX-positive ADSCs tended to diminish for several weeks. The reasons for this hFIX decline are currently under investigation. The present study showed that our tissue engineering approach based on transplantation of cell sheet format of SIV-transduced ADSCs could provide plasma hFIX levels in living mice. Further modifi cations toward achieving longevity of the ADSC sheets and their higher transgene expression levels would establish this approach to be therapeutically valuable. High levels of expression of histone deacetylases (HDACs) and hypo-acetylation of histone proteins are related with uncontrolled cell proliferation, differentiation, and pathogenesis of cancer. Thus, histone deacetylase inhibitors (HDACi) can potentially be used as anti-cancer drugs. HDACi are known to increase apoptosis of cancer cells by obstructing activity of HDACs, and increasing the accessibility of transcription factors for re-activating repressed tumor suppressor genes. An opportunity for improving HDACi activity is through the use of delivery systems that allow targeted access to cell and tissue types that are not normally a characteristic of the incorporated drug. In this study, we tested the effi cacy of the HDACi, Panobinostat (LBH589) against human T cell leukemia through encapsulation in the biodegradable polymer, PLGA using a single chain variable fragment (scFv) antibody directed to the human CD7 molecule that is exclusively expressed on human T cells to achieve specifi c delivery of the drug. The T cell-specifi c scFvCD7-conjugated drug-encapsulated PLGA nanoparticles -CD7-PLGA/LBH589 sizing at 200nm and loaded at 70% capacity, Further, systemic delivery of the formulation to tumors generated with the T cell leukemia line in immunodefi cient mice controlled tumor growth through apoptosis induction through p21 gene expression, blockade of HDAC phosphorylation and acetylation of histone proteins.
Stable and Selective Production of Therapeutic Protein in the Breastmilk of Non-Transgenic Mice Via Early Gestational Intra-Amniotic Gene Transfer

Targeted PLGA Nanoparticles Encapsulating Histone Deacetylase Inhibitor, Panobinostat Effectively Control T Cell Leukemia
Radiosensitivity of Human Induced Pluripotent Stem Cells (hiPSC) Detectable by Cell Cycle Analysis
Frank Houghton, 1 Michael W. Epperly, 1 Xichen Zhang, 1 Vishwajit Nimgaonkar, 2 Joel S. Greenberger. 1 1 Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA; 2 Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA.
Human induced pluripotent stem (hiPSC) cells are derived from differentiated somatic cells, such as fi broblasts, by over-expression of a suite of genes (OCT4, SOX2, NONOG and LIN28). Morphologically, and genetically these induced cells are indistinguishable from embryonic stem cells. hiPSCs may have clinical potential in the areas of treatment of diseases through transplantation or repair; in basic research in elucidating the factors controlling normal and abnormal differentiation; and in drug screening to identify genotoxic compounds. hiPSCs may be also valuable in identifying new small molecule radiation mitigators and protectors. We used cell cycle analysis for the determination of ionizing irradiation induced apoptosis and alteration of cell cycle distribution. hiPSC cells were grown using mTeSR1 medium (Stem Cells Technology) on matrigelcoated 6-well plates in a humidifi ed, 37oC incubator supplemented with 5% CO2. The hiPSC colonies were manually selected using a 200ul pipetter tip every 6-8 days. Once selected, these colonies were gently agitated to reduce their size and replated in a new matrigelcoated 6-well plate. The hiPSC colonies and the parent fi broblast cell line were irradiated to 0, 0.5, 1.0, 1.5, 2.0 and 2.5 Gy using a Varian linear accelerator with a dose rate of 300 cGy/min. The 6-well plates were returned to the incubator. The colonies were harvested at 24 and 48 hours post-irradiation as single cell suspensions using 0.05% Trypsin-EDTA (Invitrogen) and fi xed in cold 70% ethanol. Later, the cells were stained with propidium iodide and sorted using an Accuri C-6 fl ow cytometer. For hiPSC cells by twenty-four hours after 1.0 Gy irradiation, the percent apoptosis increased from control levels of 7.4 + 1.7% to 21.5 + 3.6% (p = 0.0069), but decreased by 48 hrs to 18.0 + 4.1% (p = 0.0297) attributable to cell death. In contrast, 1.0 Gy irradiation of the parent fi broblast line induced no detectable change in the percent apoptotic cells compared to nonirradiated cells (2.6 + 1.4%). Irradiation of parent fi broblasts to 2.5 Gy also showed no change in percent apoptosis at 24 or 48 hr (1.9 + 0.5 or 7.1 + 3.9%, p = 0.6841 or 0.384, respectively). While there was decreased viability in irradiated hiPSC cells after doses as low as 1.5 Gy (24.4 + 6.2%) compared to 0 Gy control cells (49.3 + 5.4, p = 0.0250). No signifi cant changes in viability were detected with parent fi broblasts after doses up to 2.5 Gy. There was clear alteration in cell cycle distribution in irradiated hiPSC cells: a G1 phase arrest was seen 48 hr after 2.0 and 2.5 Gy with an increase in G1 cells from 32.5 + 3.9% for 0 Gy to 47.0 + 3.6% or 45.1 + 4.4 (p = 0.0253 or 0.0275, respectively). In contrast parent fi broblasts showed no signifi cant cell cycle changes at 24 or 48 hr after either irradiation dose. Human iPSCs present a valuable system in which to identify the molecular signaling pathways controlling radiosensitivity.
Spacio-Temporal Mutagenesis in Muscle by Using AAV-Cre Vectors: The Example of the Mtm1 Gene
Romain Joubert, 1 Alban Vignaud, 1 Mickaël Le, 1 Christelle Moal, 1 Nadia Messaddeq, 2 Anna Buj-Bello. 1 1 R&D, Généthon, Evry, France; 2 IGBMC, Illkirch, France.
Manipulation of the mouse genome by site-specifi c mutagenesis using transgenic animals has been extensively used to study gene function and model human disorders. Mouse models of myotubular myopathy (XLMTM), a severe congenital muscular disorder due to loss-of-function mutations in the MTM1 gene, have been generated by homologous recombination and shown that myotubularin is essential for skeletal muscle. However, since the Mtm1 deletion occurred constitutively or shortly after birth in these mice, it is not known whether myotubularin is required during adulthood, an important issue not only in the context of muscle biology but also therapies. To delete the Mtm1 gene in adult muscle fi bers, we constructed a recombinant adeno-associated vector (AAV) that expresses the Cre recombinase under the muscle-specifi c desmin promoter. We report that a single injection of this vector into muscles of 3 month-old Mtm1 conditional mice leads to a myotubular myopathy phenotype with myofi ber atrophy, disorganization of organelle positioning and severe muscle weakness. We establish the proof-of-concept that myotubularin is required for the proper function of skeletal muscle during adulthood, and provide a valuable tissue model that is useful to study pathogenesis and evaluate therapeutic strategies. Therefore,
